Eli Lilly and Company (NYSE:LLY) is Handelsbanken Fonder AB's 4th Largest Position

Handelsbanken Fonder AB lessened its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 733,876 shares of the company's stock after selling 31,174 shares during the period. Eli Lilly and Company makes up about 2.5% of Handelsbanken Fonder AB's holdings, making the stock its 4th biggest position. Handelsbanken Fonder AB owned 0.08% of Eli Lilly and Company worth $606,116,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Petredis Investment Advisors LLC grew its position in Eli Lilly and Company by 1.2% in the first quarter. Petredis Investment Advisors LLC now owns 11,362 shares of the company's stock worth $9,384,000 after acquiring an additional 139 shares in the last quarter. Sanibel Captiva Trust Company Inc. increased its stake in Eli Lilly and Company by 10.6% in the 1st quarter. Sanibel Captiva Trust Company Inc. now owns 26,726 shares of the company's stock worth $22,073,000 after purchasing an additional 2,561 shares during the period. Curated Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 46.8% in the first quarter. Curated Wealth Partners LLC now owns 461 shares of the company's stock worth $381,000 after purchasing an additional 147 shares during the last quarter. Dividend Assets Capital LLC grew its holdings in Eli Lilly and Company by 2.2% in the 1st quarter. Dividend Assets Capital LLC now owns 1,424 shares of the company's stock worth $1,176,000 after acquiring an additional 30 shares during the last quarter. Finally, Ibex Wealth Advisors grew its holdings in Eli Lilly and Company by 6.1% in the 1st quarter. Ibex Wealth Advisors now owns 12,345 shares of the company's stock worth $10,196,000 after acquiring an additional 710 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 1.3%

Shares of NYSE LLY traded up $10.67 during trading on Friday, hitting $822.70. 1,272,756 shares of the company were exchanged, compared to its average volume of 3,640,424. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The firm has a market capitalization of $779.70 billion, a PE ratio of 70.17, a P/E/G ratio of 1.40 and a beta of 0.41. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a fifty day moving average price of $773.53 and a 200-day moving average price of $801.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the prior year, the company earned $2.58 EPS. The business's revenue was up 45.2% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a $1.50 dividend. The ex-dividend date was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.73%. Eli Lilly and Company's payout ratio is 48.82%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on LLY. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, June 7th. Finally, UBS Group dropped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.